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ABSTRACT:
Tumor progression and pregnancy share many common features, such as 
immune tolerance and invasion. The invasion of trophoblasts in the placenta into 
the uterine wall is essential for fetal development, and is thus precisely regulated. 
Its deregulation has been implicated in preeclampsia, a leading cause for maternal 
and perinatal mortality and morbidity. Pathogenesis of preeclampsia remains to be 
defined. Microarray-based gene profiling has been widely used for identifying genes 
responsible for preeclampsia. In this review, we have summarized the recent data 
from the microarray studies with preeclamptic placentas. Despite the complex of gene 
signatures, suggestive of the heterogeneity of preeclampsia, these studies identified a 
number of differentially expressed genes associated with preeclampsia. Interestingly, 
most of them have been reported to be tightly involved in tumor progression. We have 
discussed these interesting genes and analyzed their potential molecular functions 
in preeclampsia, compared with their roles in malignancy development. Further 
investigations are warranted to explore the involvement in molecular network of 
each identified gene, which may provide not only novel strategies for prevention 
and therapy for preeclampsia but also a better understanding of cancer cells. The 
trophoblastic cells, with their capacity for proliferation and differentiation, apoptosis 
and survival, migration, angiogenesis and immune modulation by exploiting similar 
molecular pathways, make them a compelling model for cancer research.
Pregnancy and malignant tumor 
One of the initial processes of human pregnancy is 
characterized by the attachment of the blastocyst to the 
uterine decidua. Implantation progresses by expanding the 
trophoblastic cells and by their differentiation into two cell 
lineages, the villous- and the extravillous trophoblasts [1]. 
The extravillous trophoblasts, proliferative and invasive, 
invade into the uterine decidua to anchor the developing 
embryo to the uterus and to establish appropriate nutrient 
and oxygen supply for the fetus [1-3]. The invasion of 
extravillous trophoblasts into the uterine wall is of crucial 
importance for fetal development, and is tightly regulated 
in a temporal and spatial manner. Its deregulation has been 
implicated in a wide spectrum of abnormal pregnancies, 
such as preeclampsia. Strikingly, these extravillous 
trophoblasts display a phenotype very similar to cancer 
cells with their capacity for proliferation, migration, 
angiogenesis and immune tolerance by exploiting 
comparable molecular mechanisms, making them an 
interesting model for cancer research [1,4-6]. 
Preeclampsia, a complex disorder
Preeclampsia, characterized by the new onset of 
hypertension and proteinuria after 20 weeks of gestation, 
is a consequence of diverse pathophysiological processes 
linked to impaired implantation, endothelial dysfunction 
and  systemic  inflammation  [7-9].  It  is  a  multisystem 
disorder unique to human, and affects 2-7% of nulliparous 
women [7]. It causes not only maternal and perinatal 
mortality and morbidity but also associates with long-
term effects on the cardiovascular complications of mother 
and child. Clinically, the affected mother demonstrates Oncotarget 2012; 3: 759-773 760 www.impactjournals.com/oncotarget
increased blood pressure, proteinuria, edema, abnormal 
clotting, and liver and renal dysfunction, whereas 
fetal preeclampsia syndrome can manifest as preterm 
delivery, growth restriction, placental abruption and fetal 
distress [10]. Preeclampsia is associated with abnormal 
placentation,  uteroplacental  vascular  insufficiency 
and altered intervillous haemodynamics, placental 
oxidative stress, and increased placental release of 
syncytiotrophoblast debris and anti-angiogenic molecules, 
which cause dysfunction of maternal endothelial cells and 
a systemic inflammatory response [8,11]. 
Despite intensive research, a full understanding 
of the pathogenesis of preeclampsia remains elusive. 
Several mechanisms have been implicated in the etiology 
of preeclampsia, including immunological abnormality, 
defect in vascular/ischemic modeling, deregulated 
inflammatory  factors,  lipid  and  metabolic  disorder, 
failures in regulatory pathways of hormone synthesis and 
prostaglandin action [8]. Particularly, while immunologists 
consider preeclampsia as a maternal-embryonic immune 
maladaptation [12,13], vascularists propound that 
ischemia-reperfusion leads to oxidative stress and vascular 
disease [14,15]. Both of these aspects may be important 
for preeclampsia pathogenesis [16]. A two-stage model 
has been recently proposed in which the initiating event, 
poor placentation, is thought to occur early in gestation 
[11,17]. At this stage of preeclampsia, the most affected 
area of the placenta is the basal plate, where trophoblast 
invasion takes place. Interstitial trophoblast invasion is 
often shallow, and endovascular invasion does not proceed 
beyond the terminal portions of the spiral arterioles [18-
20]. Thus, the placental development fails to meet the 
gestation-related fetal demands for increased blood flow. 
The second stage of preeclampsia is thought to be the 
maternal response to defected placentation, and systemic 
endothelial dysfunction appears to be the major picture for 
preeclampsia [11,17]. There are differences between early- 
and late onset preeclampsia regarding clinical presentation 
and outcome [8,16]. Histopathological examination of 
placenta also shows different morphological characteristics 
depending on the timing of disease onset [21]. Whether 
these differences are a reflection of differential placental 
gene expression is not yet clear. 
The placenta, the main stage of these processes, 
plays  a  central  role  in  preeclampsia  pathogenesis  [7-
9,16,17].  It  is  generally  believed  that  preeclampsia 
originates in the placenta, since preeclampsia ends with 
delivery and removal of placental tissue. Therefore, 
placenta-based investigations are of importance for 
understanding of disease initiation and progression. 
Microarray-based  transcriptional  profiling  becomes  a 
valuable tool for identifying disease-related genes and 
pathways [22]. This approach has been widely used for 
analysis of preeclampsia [23]. In this review, we will 
summarize the recent data from the gene analysis studies. 
Furthermore, we will focus on several interesting genes 
identified  in  these  studies  and  analyze  their  potential 
function in preeclampsia, compared to the roles in 
malignant tumor cells. 
Microarray gene profiling in preeclampsia
Searching the microarray-based placental studies 
associated with preeclampsia in Pubmed, we have 
collected 18 studies from June of 2007 to June of 2012 
[23-39], with 220 placenta samples from preeclampsia 
patients and 224 from controls. Among these studies, 
seven were designed with relatively comparable 
gestational age [23,27,28,30,31,33,34] and 9 with same 
mode of delivery (cesarean section) [24,25,30,31,34,36-
39]. As listed in Tab. 1, the sampling sites varied and 
microarray plate forms were different. In addition, 
strategy of data analysis differed. In general, the 
differentially expressed genes from these studies include 
genes coding for multicellular structure development and 
differentiation, activity of immune response, angiogenic 
and vasculogenic responsible proteins, cell proliferation 
and  apoptosis,  inflammation  related-molecules,  and 
metabolism associated-proteins. The results from these 
18 microarray-based studies are apparently diversified 
and even occasionally controversy concerning the genes 
and pathways of interest. A major part of the divergence 
could probably be ascribed to matching variability, such 
as gestational age, induction of labor, mode of delivery, 
maternal ethnicity, varied placental sampling sites, 
different types of microarray chips and platforms, distinct 
data filtering strategy and diverse statistical analysis. 
Among these 18 microarray studies, two dealt with 
early and late onset of preeclampsia [29,33], and the data 
show that they share some genetic features yet differ in 
other signatures suggesting these two types might have 
different pathogenesis. As the alteration of genes triggering 
preeclampsia has been thought to take place at a very early 
stage of gestation, gene analysis using placental samples 
after delivery may include both causative factors as well as 
secondary responses. Of note, one of these 18 studies was 
based on chorionic villous samples from 10-12 gestational 
weeks with the interestingly results that deregulated genes 
are mainly involved in inflammation, immune response 
and cell motility [23]. The results have been underlined by 
another study based on chorionic villous samples yet using 
quantitative PCR, showing that genes linked to trophoblast 
invasion and utero-placental hemodynamic adaptation are 
altered already in the first trimester [40]. 
In general, the results from these studies deliver 
multiple pictures of gene signatures, highlighting the 
complicated pathophysiology and heterogeneous causes 
of this disease. Despite the complex and inconsistence in 
gene signatures, the observations from these 18 studies 
show nevertheless some overlapping genes and pathways 
associated with preeclampsia, as discussed below. As one 
single gene is very often involved in several molecular Oncotarget 2012; 3: 759-773 761 www.impactjournals.com/oncotarget
networks, we will discuss it only in one signaling pathway.
I. Angiogenesis and vasculature pathway
From these 18 microarray studies in preeclampsia, 
the most repeatedly reported genes are fms-like 
tyrosine kinase 1 (FLT1) and endoglin (ENG) [25,27-
29,29,30,32,34-37].  Other  differentially  expressed 
angiogenesis-related genes have also been reported, such 
as platelet derived growth factor A (PDGFA),[25] EGF-
like-domain, multiple 7 (Egfl7) and Activin A receptor 
type II-like I (Acvrl I) [33], vascular endothelial growth 
factor (VEGF) [25,30], FLT4 and platelet derived growth 
factor D (PDGFD) [29]. In addition, the differentiated 
expression of other angiogenic genes have been also 
observed,  including  JAG1  (a  signaling  factor  which 
stimulates angiogenesis in endothelial cells), ECGF1 
(endothelial cell growth factor, platelet-derived) and 
COL18A1 (collagen, type 18, A1, a potent anti-angiogenic 
protein) [25]. These data underscore the recent observation 
that an imbalance in circulating factors with pro- and 
anti-angiogenic/vasculogenic functions, such as soluble 
vascular endothelial growth factor receptor 1 (VEGFR1, 
sFlt-1), placental growth factor (PlGF), and transforming 
growth factor co-receptor endoglin, is important in the 
pathogenesis of preeclampsia [41-44]. 
FLT1
Members of the VEGF family are critical factors 
involved in placental angiogenesis and play functional 
roles in the adaptation mechanisms of neovasculogenesis 
in response to the compromised placental oxygen delivery 
in  preeclampsia.  The  hypoxia-induced  factor  1  (HIF-
1) induces expression of angiogenesis-related genes, 
such as FLT1, and oxygen-regulated genes [45,46]. Two 
mRNAs are generated from the FLT1 gene in placenta and 
vascular endothelial cells, a long form for the full-length 
receptor FLT1 and a short form for soluble FLT1 (sFLT1), 
which  carries  only  the  ligand  binding  region  [47,48]. 
This short form of the mRNA is generated by premature 
polyadenylation within intron-13 [49,50]. In the placenta, 
Figure 1: Illustrative scheme of the common features shared by normal pregnancy and tumor development. While 
extravillous trophoblasts in the placenta are capable of migrating into the uterine decidua to establish appropriate nutrient and oxygen 
supply for the fetus development, malignant tumor cells have the capability to successfully invade their neighboring tissues to set up the 
friendly microenvironment for further progression. Moreover, both of them have the competence to establish effectively angiogenesis 
and to escape successfully the host immune defense system.  In preeclampsia, however, trophoblasts fail to fulfill these tasks by showing 
defective invasion, altered angiogenesis and violent immune response. The interesting genes identified from the 18 microarray-based 
placental gene profiling are listed and described in the text. ST, syncytiotrophoblast; CT, cytotrophoblast. The figure design is inspired by 
Holtan et al, [4].Oncotarget 2012; 3: 759-773 762 www.impactjournals.com/oncotarget
Table1: Summary of microarray studies in preeclampsia
Author Group
Mother 
age
Gest. age
(wks)
BMI MOD Sampling Microarray  Finding Hot genes  Pathways
Jarvenpaa
2007 Finland
2 PE + 
IUGR
3 ctrl
21.5
27.7
35.7
38.5
20
27.3
Cs 
without 
labor
Not described
Affymetrix 
Human U133 
plus 2.0
4 genes up 
9 genes down 
Up: EPAS1, 
FLT1, 
SIGLEC10, 
ANG4
Down: ECGF1, 
JAG1, Palladin, 
COL18A1, 
TNFSF12, 
VEGF, ANPEP, 
PDGFA, 
SERPIN12
Angiogenesis
Centlow 
2008 Sweden  
10 PE
5 PE 
+notch
5 notch
15 ctrl
28.5±2.9
32.4±4.3
31.8±5.8
31±3.3
37.7±2.3
35.0±4.1
38.9±3.1
40.0±1.4
   Cs/vag.
Villous tissue from 
central part of 
placenta, frozen on 
dry ice and stored at 
-80°C.
Operon 
v 2.1 human 
70 mer oligo 
set 
30 genes were 
altered in at 
least one fold 
between-group 
comparison.
Up: Hbα2, Hbγ 
and Hbβ in PE 
vs. ctrl.
Potent toxins:
endothelial 
damage,
inflammation
Toft                 
2008
Norway    
10 PE
8 SGA
10 PE+ 
SGA
30.3±5.4
34.4±5.0
30.3±4.9
34.2±2.5 
34.5±3.8 
33.9±2.0 
Cs 
Tangentially 
dissection from the 
maternal side close 
to umbilical cord, 
stored at -80°C.
Affymetrix 
HG  U133 
plus 2.0 
No difference 
between study 
groups.
qPCR: FLT1 
and ENG are 
up regulated in 
PE+SGA group
Angiogenesis
Enquobahrie
2008
USA
18 PE
18 ctrl
32.6
30.0
35.8 
38.9 
27.0
25.3
10 Cs 
7 Cs
Pooled of 4 samples 
from maternal side, 
stored at -80°C. 
Operon
Human 
genome array 
ready oligo 
set
1164 genes 
altered in PE vs. 
ctrl. 58 genes (56 
up and 2 down 
regulated) had an 
absolute change 
≥1.5. 
Up: LEP, FLT1, 
PCDHA3, 
CYP11A, F2R, 
IL9,  FCGR2B,   
CDO1, 
VGLL1, 
EBI3, INSL4, 
BCL6,INHA
Down:
MGC1132, 
NR4A2
Reproductive 
physiology, 
immune response, 
cytokines, 
cell cycle 
Winn 
2009 
USA  Denmark
12 PE
11 PTL
30.7±9.1
30.2±7.1
32.1±3.3 
31.0±4.6 
6 Cs/10 
labored
2 Cs/11 
labored
Basal plate, 
Snap frozen.
Affymetrix
HG-U133A / 
HG-U133B  
55 genes 
differentially 
expressed.
Up: FLT1, 
LEP,  CRH, 
SIGLEC6, 
PAPPA2,
INHA,  ENG, 
HTRA1
Lipid metabolism, 
angiogenesis
Sitras 
2009 
Norway
16 PE 
severe 
PE
21 ctrl
30.5±5.2
30.2±4.8
34.0±3.6
39.6±1.3
25.9±4.8
24.8±5.3
11 Cs
8 Cs
Chorionic tissue,
2 cm beside 
umbilical cord 
middle layer of 
placenta, 
stored at -80°C.
Applied 
Biosystems
Human 
genome 
survey 
microarray 
v2.0 
213 genes up and 
82 down in PE vs. 
ctrl. 
36 up and 132 
down in early- vs. 
late onset of PE. 
Up:LEP, 
FLT1, FLT4, 
β-hCG,  ENG, 
LAEVERIN, 
BCL6, 
INHA, 
MMP14, 
PAPPA2 
Down: 
PDGFD
PE vs. ctrl:
Angiogenesis,
Oxidative 
stress, 
inflammation early 
vs. 
late:
endothelial 
signaling 
Founds
2009
USA 
(CVS)
4 PE
8 ctrl
36.5±0.6
38.1±3.1
11.4±0.7 
11.3±0.6 
29.9±4.2
24.5±4.0
Cs/vag.
Chorionic villous 
sample at 10-12 wks. 
Affymetrix 
HG-U133 
Plus 2.0 Gene 
Chip 
5 up and 31 down 
in 1st  trimester 
in PE vs. ctrl.
Up:CCK, 
CTGA2 
Down: FSTL3, 
MMP12, 
LAIR2, 
S100A8
Inflammation, 
immune
regulation, 
cell motility
Lee 
2010 
Korea
13 PE 
severe 
13 ctrl
31.85±
3.93
33.08± 
4.65
35.93± 
0.9 
38.48±
0.56
Cs 
without 
labor
Central area, stored 
at  -80°C.  Pooled 
RNA.
Agilent 
Human 
4X44K 
121  up  and  294 
down in PE vs. 
ctrl.
Up: CXCR6, 
CXCL3, OSM, 
LEP, FLT1, 
VEGFA,
SMOX, 
CYP26A, 
EGLN3, 
LDHA, 
CRY2L1
AngiogenesisOncotarget 2012; 3: 759-773 763 www.impactjournals.com/oncotarget
Hoegh 
2010
Denmark
11 PE
18 ctrl
Cs/vag.
Maternal 
side, center of 
cotyledons, 
stored 
differently, 
Pooled RNA.
Affymetrix
HG-U133A 
Gene Chip 
12  up  and  9 
down in PE 
vs. ctrl.
Bradykinin B1 
receptor, 
14-3-3, INHBA, 
LEP
Placentation, 
oxidative stress, 
inflammation
Várkony
2011
Hungary
6 PE
6 PE+ 
HELLP
5 ctrl 
preterm
5 ctrl 
term
34.3
28.7
31.6
30.8
32.4 
30.7 
31.0 
38.9 
24.3
23.7
23.4
26.7
Cs
Villous tissue 
from central 
cotyledons 
close to 
umbilical cord, 
stored at -80°C.
Agilent 
44K whole 
human 
genome 
oligo 
181 altered 
in preterm vs. 
term, 350 in 
PE vs. ctrl and 
554 in HELLP 
vs. ctrl.
Up: LEP, CGB, 
TREM1,  LHB, 
SIGLEC6, 
PAPPA2
Down:  KRT81, 
OPRK1
Multicellular 
structure, 
differentiation 
neuroactive ligand- 
receptor interaction
Tsai
2011 
USA
23 PE
37 ctrl
33.6±3.7
37.6±1.93
Induc-
tion of 
labor
Fetal side, 5 cm 
from umbilical 
cord, in liquid 
nitrogen
Illumina
Human6- v2 
BeadArray 
128 altered
in PE vs. ctrl.
ENG, PAPPA2, 
RDH13, INHA, 
LEP, FLT1, 
SIAE, SIGLEC6
Immune response
Chang
2011 Taiwan 
13 PE
10 ctrl
7  PE 
super-
impose
28.1±1.4
33.2±1.6
33.5±1.9
33.5±0.9 
38.8±1.0 
34.2±1.2 
Not 
descri-
bed
Maternal side, 
stored at -80°C.
Human  15K 
chips
Up: HSPA1B, 
LIMS1, PLAGL1, 
TRIM31, 
PPP2R2C
Down:  RNF128, 
ADM, ARFIP1
Development,
apoptosis, 
cell death
Kang
2011 
Korea
16 PE
17 ctrl
31.7±3.9
33.1±4.2
36.1±2.4
39.0±0.9
Cs 
without 
labor
Chorionic 
tissue,  near 
umbilical cord, 
in liquid 
nitrogen.
GE 
healthcare 
Human 
whole 
genome 
bioarrays 
132 altered, 
in PE vs. ctrl.
UP: FLT1, LEP
ITGA5, EBI3
SIGLEC6,
HTRA1
Proliferation,  
differentiation
immune,
biosynthesis, 
transport of lipid or 
protein
Nishizawa
2011
Japan
8  PE 
severe
8 ctrl
8 FGR
31.0±4.7
31.5±6.5
31.4±3.7
34.4±1.8 
38.1±0.8 
37.3±1.0 
21.7±3.7
21.4±2.3
19.9±1.9
Cs 
without 
labor
Sections of 
placental villi 
between the 
basal and 
chorionic 
plates, in liquid 
nitrogen.
Affymetrix 
Human Exon 
1.0 ST Array 
94 up and 88 
down at least 
1.5 fold in PE 
vs. ctrl. 30 up 
and 32 down 
of these in 
FGR.
Up:  INHBA, 
INHA,  FLRG, 
BCL6, LEP, 
UP:PAPPA2, FLT1, 
ENG, CGB, CRH
Down: GSTA3
p53  targets,  
cell growth, 
differentiation
Mayor-Lynn 
2011
USA
7 PE
7 PTL
7 ctrl
23.8
(20-26)
28.3
(22-35)
30(21-38)
35 (31-39)
28 (24-33)
38 (37-39)
38.2
30.8
37.5 Cs
Villous tissue. 
Illumina 
Human
Ref-12 v3 
Expression 
BeadChip
120 altered in 
PE and PTL 
compared to 
ctrl.
CRH,SOCS1,
MMP1, MMP9, 
ADAM17, 
ADAM30, 
TIMP3, STC2, 
CRHBP, EDN2
Inflammation,    cell 
cycle, cell-to-cell 
signaling, Embryonic 
development
Junus
2012 Sweden
Early
8 PE  
4 ctrl 
late:
7 PE 
6 ctrl 
31.5±5.0
34.0± 4.5
30.0±11.5
24±4.5
29.3±3.0
24.4±1.6
39.9±1.9
40.2±2.2
8 Cs
vag.
1 Cs
2 Cs
Central part of 
placenta 
stored at -80°C.
Operon v 2.1 
human  70-
mer oligo set 
88 up and 108 
down in early- 
vs. late onset. 
Down in early: 
ACVRL 1, EGFL7, 
ROBO4, IDO 1 
Angiogenesis, cell 
motility, oxygen 
transport 
Meng 
2012
China
6 PE
6 ctrl
26.0±4.3
28.5±1.9
36.4±0.9
39.0±0.7
Cs 
without 
labor
Sections from 
maternal face 
of the placenta
Stored at -80°C
Illumina 
Human
HT-12  V4 
BeadChip
483  up  and 
456 down at 
least 2 fold in 
PE vs. ctrl. 
Up:  BTNL9. 
HMBS.  ULBP1, 
CHRNA1, RMRP
Down: INSL6, 
CXCL9,  TMCC1, 
PAGE2
Cellular function 
and development, 
cell signaling, lipid 
metabolism
Lapaire
2012
Switzerland
9  PE 
severe
7 ctrl
36.8
(22-43)
35.1
(33-37)
34.6
(33-39)
38.6
(38-41)
26.3
(30-34)
21.1  (19-
37)
Cs
Cs
Villous tissue, 
stored at -80°C.
Affymetrix 
GeneChip 
Human  1.0 
ST Arrays
896 
differentially 
expressed.
Up:  βhCG, 
HTRA4,  CRHBP, 
LHB,  QPCT, 
CD97,  MMP19, 
ADAM2, INHBC
Down: CCL3, 
NOX4, VCAM1, 
FOSB, CX3CR1
Riboflavin 
metabolism, 
leukocyte 
extravasation, NF-
κB  and  chemokine 
signaling
Cs: Cesarean section; vag: vaginal delivery; PTL: preterm labor; PE: preeclampsia; HELLP: haemolysis, elevated liver enzymes and low platelets; SGA: 
small for gestational age; BMI: body mass index; MOD: mode of delivery; wks: weeks; ctrl: control; FDR: false discovery rate; IUGR: intrauterine growth 
restriction; FGR: fetal growth restriction; Up: upregulted; Down: downregulated.Oncotarget 2012; 3: 759-773 764 www.impactjournals.com/oncotarget
trophoblasts expressing FLT1 have much more sFLT1 
than the full length FLT1 [51]. Indeed, its overexpression 
is repeatedly reported to be elevated in preeclampsia 
in these microarray-based studies, as described above, 
regardless of varied sampling sites, or early and late onset 
of preeclampsia. Enhanced expression of the FLT1 gene 
in preeclamptic placenta is consistent with the observation 
that sFlt1 is increased in the maternal circulation in women 
destined to develop preeclampsia [52,53]. sFlt1 binds to 
and antagonizes both VEGF and PlGF by preventing them 
interacting with their endogenous membrane receptors 
and induces thereby endothelial dysfunction [50,54]. In 
support of this idea, overexpression of sFLT1 has been 
shown to induce preeclampsia in rats, highlighting that 
sFlt1 inhibits angiogenesis and contributes to the placental 
insufficiency of the pathogenesis of preeclampsia. These 
data also imply that sFlt1 is an attractive target for treating 
preeclampsia, as demonstrated by a pilot study [55].
Tumor progression is invariably associated with 
hypoxia, a common state of cancer cells due to the lack 
of blood supply to the rapidly growing tumor [56]. 
Insufficient oxygenation has opposing effects on cancer 
cells: limiting tumor cell division as well as promoting 
tumor  cell  more  aggressive  and  invasive  [57].  Like 
trophoblasts in placenta, the response of tumor cells to 
oxygen deprivation is also driven by hypoxia induced 
factor-1  (HIF-1).  HIF-1  is  the  key  factor  mediating 
adaptive response to hypoxia, and is degraded under 
normal  condition  by  prolyl  hydroxylases  (PHD)  and 
accumulated upon hypoxia [58]. Tumor cells are induced 
to secrete pro-angiogenic factors such as VEGF to form 
the  new  blood  vessels  [59],  and  activate  an  invasive 
program mediated by the c-Met/HGF (hepatocyte growth 
factor) pathway [60]. Therefore, like in normal pregnancy, 
the VEGF-VEGFR system plays critical roles in tumor 
progression, making it an interesting target for cancer 
therapy. Blocking the VEGF-VEGFR system, like the 
function of sFlt1 in preeclampsia, has been regarded as 
a powerful strategy for cancer therapy. In fact, the anti-
VEGF neutralizing antibody bevacizumab and multi-
tyrosine kinase inhibitors such as sorafenib and sunitinib 
have been developed and are widely used in the treatment 
of cancer [61,62]. In most cases, these agents improve 
progression-free survival and overall survival. However, 
frequent side effects of these anti-VEGF-VEGFR agents 
are hypertension and proteinuria, indicating a close 
relationship between deregulated VEGF and hypertension/
proteinuria, characteristic of preeclampsia [63]. The data 
also suggest that desired agents should target selectively 
tumor-related angiogenesis [64], not the systemic VEGF 
function.  
ENDOGLIN (ENG)
In addition to FLT1, the ENG gene is also increased 
in the preeclamptic placenta, reported by several groups 
[28,29,32,34,35,37]. ENG codes for endoglin, which is 
a co-receptor for transforming growth factor β1 and β3 
(TGF-β1 and TGF-β3) on cell membranes of endothelium 
and syncytiotrophoblast cells. In endothelial cells, TGF-β 
signals activate the Smad-dependent as well as the Smad-
independent signaling pathway, to regulate fundamental 
cellular processes, including proliferation, differentiation, 
migration, apoptosis, adhesion, cytoskeletal organization 
and extracellular matrix remodeling [65,66]. Endoglin is 
highly increased in the maternal serum of preeclamptic 
women and may cooperatively act with sFlt1 to induce 
severe preeclampsia [67]. Its level falls after delivery and 
correlates with disease severity [67]. Endoglin decreases 
endothelial nitric oxide signaling by inhibiting TGF-β1, 
leading  to  endothelial  dysfunction  [67,68].  Moreover, 
endoglin activates eNOS [68,69] as well as interacts and 
modulates Activin receptor-like kinase-1 and -5 signaling 
[69], resulting in the potentiation of Smad1 and Smad2 
and  inhibition  of  Smad3  [69,70],  thereby  disrupting 
homeostasis and causing the development of preeclampsia 
[69]. In addition, endoglin decreases arterial diameter 
of rat renal micro-vessels by modulating TGF-β1 and 
TGF-β3  mediated  vasodilation  [67].  Soluble  endoglin 
cooperates with sFlt1 to induce endothelial dysfunction 
in human umbilical vein endothelial cells (HUVECs), 
and simultaneous administration of both causes a severe 
preeclampsia-like  illness  in  rats  [41,52,67].  Taken 
together, the data suggest that endoglin plays an important 
role in the pathogenesis of preeclampsia.
Interestingly, ENG expression strongly results 
in  active  vascular  endothelial  cells  in  tumor  [71]. 
Endoglin in the blood vessel endothelium is involved in 
the control of cell proliferation, migration and capillary 
tube formation, and plays a pro-angiogenic role in tumor 
development [71,72]. Furthermore, endoglin suppresses 
cancer metastasis, which is associated with decreased 
expression in several Smad1-responsive genes [73]. It 
appears that tumor cells and trophoblastic cells exploit 
the same angiogenesis mechanisms involved in tumor 
progression and in placental development in pregnancy. 
Endoglin has been also suggested as an appropriate marker 
for tumor-related angiogenesis and neovascularization and 
numerous studies demonstrate the potential of endoglin in 
tumor diagnosis, prognosis and therapy [71]. Compared to 
Flt1, endoglin is possibly a more specific target for cancer 
therapy, since its expression is more tumor-related. Thus, 
targeting endoglin has been attracting high attention as 
a promise therapeutic strategy in human malignancies. 
Among therapeutic agents, monoclonal antibodies have 
shown anti-tumor efficacy. Several studies demonstrate a 
long-lasting suppression of tumor growth and metastasis Oncotarget 2012; 3: 759-773 765 www.impactjournals.com/oncotarget
in immune deficient mice by administrating antibodies 
[74,75],  possibly  by  inhibiting  tumor-associated 
angiogenesis, and/or by destructing tumor-associated 
vasculature. Recently, it has been shown that TRC105, a 
chimeric IgG1 monoclonal antibody binding to endoglin, 
inhibits tumor angiogenesis and appears to have a safety 
profile in a clinical phase I trial [76]. Importantly, classic 
toxicities associated with VEGF inhibition, including 
hypertension, proteinuria and thrombosis were not 
prominent [76], suggesting that endoglin is a selected 
target for debating tumor-associated angiogenesis. 
PlGF
Interestingly, no distinct differential expression 
of the placental growth factor (PlGF) was reported 
from these 18 studies. PlGF is a pro-angiogenic protein 
and member of the VEGF family produced by villous 
syncytiotrophoblasts in the placenta [77]. Previous studies 
have demonstrated that levels of circulating PlGF in the 
serum  of  patients  with  preeclampsia  are  significantly 
decreased compared with normotensive controls [41,78]. 
This discrepancy is possibly ascribed to the fact that 
PlGF decreases in the maternal circulation already 
several weeks before the onset of preeclampsia [79], or 
alternatively, the down-regulation of PlGF happens only 
in a minor population of trophoblasts, which is difficult 
to be reflected by global gene analysis with whole cell 
populations of placenta.
II. Immune and defense response
Active avoidance of tumor cells from elimination by 
immune cells is one of cancer hallmarks [80] and restored 
antigenicity and immunogenicity of tumor cells by agents, 
such as metformin [81], may represent a novel strategy 
for cancer prevention and treatment. Like in tumor 
progression, immune tolerance is of critical importance for 
placental development and deregulated immune response 
is associated with pathogenesis of preeclampsia. Based on 
the results from these 18 studies, one of the most striking 
genes is sialic acid binding Ig-like lectin 6 (SIGLEC6), 
which  is  generally  elevated  [27-29,31,32,36].  Other 
differentially expressed genes involved in immune and 
defense response include sialic acid acetyl esterase (SIAE) 
and ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
(ST6GAL1) [32], and Epstein-Barr virus induced gene 3 
(EBI3) [27,36,37,39]. Interestingly, B-cell CLL/lymphoma 
6 (BCL6) is shown to be increased [27,37]. In addition, 
31 genes involved in the CXC chemokine receptor 4 
(CXCR4) signaling were differentially expressed in 
preeclamptic placentas, compared to normal controls [32]. 
Finally, other immune and defense response related-genes 
are also reported to be deregulated, such as FCGR1A, 
FCGR2B,  IL9,  NR4A2,  PROCR  and  IFIT4  [27]. 
Collectively, the genes associated with immune response 
are obviously altered in preeclampsia.
SIGLEC6
Siglecs, sialic acid binding immunoglobulin-like 
lectins, are a family of cell surface receptor proteins 
which recognize sialylated glycans and transmit signals 
to immune cells, regulate cellular activation in the 
immune system [82,83]. They are characterized by an 
N-terminal V-set immunoglobulin domain that mediates 
sialic acid binding followed by varying numbers of C2-
set immunoglobulin domains [84]. Siglec6 was originally 
identified both as a leptin-binding protein (obesity binding 
protein-1 or OB-BP1) and as a placental protein [85,86]. 
Further analysis demonstrates that high expression 
of Siglec6 is found to be strictly only on cyto- and 
syncytiotrophoblasts in placenta and on B cells in human 
[86].  Its  cytosolic  part  contains  the  immunoreceptor 
tyrosine-based inhibitory motif (ITIM) and the ITIM-
like domains. Receptors with ITIM function as inhibitory 
receptors via recruitment of cytoplasmic phosphatase 
with Src homology 2 (SH2) domain [87]. The molecular 
function of Siglec6 in placenta is not yet understood. It 
has been implicated in being associated with regulating 
cellular  activation  within  the  immune  system  [84], 
and could play a role in term labor [88]. Recently, an 
interesting study shows that Siglec6 interacts with 
glycodelin-A (GdA) to suppress trophoblast invasiveness 
by inhibiting extracellular signal-regulated kinase (ERK)/
c-Jun signaling pathway [89]. 
Interestingly, in spite of varied sampling sites 
or early/late onset of preeclampsia, increased gene 
expression of SIGLEC6 is repeatedly observed in 
microarray gene profiling studies in preeclamptic placenta 
[27-29,31,32,36], implying deregulated SIGLEC6 may 
be tightly associated with pathogenesis of preeclampsia. 
Given that Siglec6 is to be found only in human placenta 
and preeclampsia is regarded as a uniquely human 
disease [90], the molecular roles of Siglec6 in villous 
cytotrophoblasts and syncytiotrophoblasts, and in 
extravillous cytotrophoblasts, in association with leptin, 
warrant further and deep investigations, in context of 
invasion process of cytotrophoblasts and immune defense 
response in decidua. Moreover, it is intriguingly to address 
whether  the  deregulated  GdA/Siglec-6/(ERK)/c-Jun 
network could be responsible for the shallow invasion 
characteristic in preeclampsia placenta [89]. Importantly, 
the  gene  and  protein  level  of  Siglec6  is  specifically 
increased in primary pulmonary mucosa-associated 
lymphoid tissue (MALT) [91]. Whether it has a role in the 
pathogenesis of the MALT remains to be clarified.  Oncotarget 2012; 3: 759-773 766 www.impactjournals.com/oncotarget
EBI3
EBI3, involved in immune/defense response, is an 
interesting gene differentially expressed in preeclamptic 
placentas [27,36,37,39]. Trophoblasts are thought to play a 
key role in maternal tolerance to the semiallogeneic fetus, 
in part through cytokine production and natural killer 
cell interaction. EBI3 encodes a soluble hematopoietin 
receptor related to the p40 subunit of interleukin-12 
(IL-12) [92]. It is highly expressed in placental cells in 
pregnancy, including syncytiotrophoblasts and extravillous 
trophoblasts [93]. In addition, EBI3 levels are strongly up-
regulated in circulation of pregnant women and gradually 
increased with gestational age. These data, together with 
the finding that EBI3 peptide is presented by HLA-G, 
suggest that EBI3 is a critical immune modulator in the 
fetal-maternal relationship. Moreover, EBI3 has been also 
shown to associate with p28 to form IL-27, a heterodimeric 
cytokine with important immune regulatory functions 
[94]. It has been reported that syncytiotrophoblast cells as 
well as extravillous trophoblast cells invading the decidua 
are found to express the both peptides of IL-27, namely 
EBI3 and p28, suggesting that IL-27 may be linked to 
the cytokine network regulating local immune responses 
in pregnancy [95]. As EBI3 expression in extravillous 
trophoblast cells is to be tightly regulated, it is important 
to investigate the role of increased EBI3 in preeclampsia. 
EBI3 has roles not only in maintenance of 
pregnancy or immune tolerance of the human maternal 
body toward the fetus, but also in Hodgkin’s lymphoma 
and adult T-cell lymphoma/leukemia [96,97]. Moreover, 
EBI3 is also found to have a crucial role in human lung 
cancer development and is implied to be responsible for 
growth and malignancy of lung tumors [98]. However, 
the detailed molecular role of EBI3 in oncogenesis is not 
understood. It is tempting to speculate that, combined with 
p28 to form IL-27, expression of EBI3 is maybe linked to 
immune response in cancer cells. It is thus of importance 
to study the association of EBI3 expression with other 
human malignancies and its molecular roles in tumor cell 
development.
III. Motility and invasion
Superficial  invasion  of  extravillous  trophoblasts 
and impaired spiral artery remodeling are hallmarks 
in preeclampsia. Invasion of extravillous trophoblastic 
cells into maternal uterine tissues is essential for 
successful placental development and progression 
of pregnancy. Whereas endovascular trophoblasts 
migrate into the maternal spiral artery for remodeling, 
interstitial trophoblasts invade the decidual stroma and 
communicate with its diverse cell types, such as stromal 
cells, macrophages and uterine natural killer cells, for 
a  supportive  microenvironment  [99].  In  contrast  to 
malignant cells, trophoblast invasion and spiral artery 
remodeling are tightly controlled. Many pathways 
observed in cancer cells are used by invasive extravillous 
trophoblasts, like PI3K/AKT/mTOR, STAT/JAK, Notch 
signaling and integrin/FAK/Rho pathways [99]. A great 
body of studies demonstrates that these pathways are 
altered  in  preeclampsia.  Among  these  18  studies,  in 
combination with previous data from microarray gene 
profiling,  several  studies  pointed  out  that  the  factors 
responsible for motility and invasion of trophoblasts were 
altered, in particular, matrix metalloproteinases (MMPs) 
and tissue inhibitor of metalloproteinases (TIMPs), such 
as MMP1, -9 and S100A9 [39], MMP14 [28], MMP12, 
S100A8 [23], MMP10, -13, -15, TIMP2 and -3 [100]. The 
MMPs are a family of enzymes involved in degradation of 
extracellular matrix and have critical roles in trophoblast 
invasion. However, the results of one study could not be 
repeatedly reported by another, which could be resulted 
from varied placental sampling sites and gestational age. 
On the other hand, MMPs have long been thought to be 
essential for basement-membrane penetration during 
metastasis of cancer cells, and are especially associated 
with highly aggressive late-stage tumors with poor clinical 
outcome [101]. To understand the invasion working 
mechanism of trophoblasts in placenta, which is altered 
in preeclampsia, is doubtlessly useful for providing new 
targets for cancer intervention.
VI. Apoptosis, cell survival and differentiation-
related genes
Apoptosis, programmed cell death, is critical 
for normal placental development, including placental 
invasion, cytotrophoblast fusion, and syncytiotrophoblast 
function as well as trophoblast-mediated spiral artery 
remodeling in placenta. Increased apoptosis is associated 
with preeclampsia, possibly trigged by hypoxia and 
reactive oxygen [102]. It has been reported that the activity 
of caspase-3, the downstream effector of intrinsic and 
extrinsic apoptosis pathways, is increased [102], whereas 
BCL-2, an important inhibitor of apoptosis, is decreased 
in syncytiotrophoblast cells [103] and extravillous 
trophoblasts [104]. Moreover, Fas and FasL are altered 
in villous trophoblast cells in preeclampsia [105]. In 
addition, Smac (second mitochondria-derived activator 
of caspase) was significantly elevated, evidenced by the 
staining in syncytiotrophoblasts, cytotrophoblasts and 
endothelial cells in preeclampsia [106]. By contrast, XIAP 
(the X-linked inhibitor of apoptosis protein) and survivin, 
two critical inhibitors of apoptosis, were not altered in 
preeclampsia [106]. 
Intriguingly,  only  one  among  the  18  microarray 
studies observed that apoptosis-related genes, BAX, 
FASLG and p53AIP, were up-regulated in preeclampsia 
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caspase-10,  death-receptor  3  were  altered  [107].  Yet, 
other gene analysis studies could not make the same or 
similar observations. The data imply that the alteration of 
apoptosis gene expression could take place at very early 
stage of preeclampsia, or these genes are differentially 
expressed only in a small population of placental cells, 
which is not evident with whole RNAs from highly 
heterogeneous cell types of placenta. This issue could 
be addressed by using laser-based technology to select 
homologous single cells for gene microarray analysis. 
Alternatively, deregulated apoptosis-associated proteins, 
observed by immunohistochemistry as described above, 
come not from altered gene expression, rather from varied 
post-transcriptional modification, like some microRNA, 
not affecting the gene level but interfering with 
translation; or post-translational modifications, such as 
phosphorylation and ubiquitination, which impact protein 
stability, localization, interaction partners and molecular 
function. In addition, aponecrosis, incomplete execution 
of apoptosis followed by degeneration via necrosis, may 
get more attention in delineating the pathogenesis of 
preeclampsia [108], as it allows syncytial knots to keep the 
ability of inducing inflammatory response of the mother, 
characteristic for preeclampsia. 
BCL6
BCL6 is the master regulator of the germinal center 
reaction and a key oncogene in B cell lymphomagenesis 
[109]. It is a transcriptional repressor which recruits the 
repression machinery directly or through several co-
repressors into the regulatory regions of its targets. The 
biological roles of BCL6 in normal B cell development 
and lymphoma oncogenesis have been intensively studied 
by  the  identification  of  the  full  set  of  genes  that  are 
targets of its transcriptional regulatory function [109]. 
This set of BCL6 targets points to a number of cellular 
functions which are likely to be controlled by BCL6 
during germinal center development, including survival 
and DNA-damage response genes, like TP53, ATR (ataxia 
telangiectasia and Rad 3 related) and CHEK1 (checkpoint 
kinase 1), and cell cycle arrest gene CDKN1A/p21 [109-
113]. BCL6 prevents thereby premature activation and 
differentiation of germinal center B cells and provides 
an environment tolerant of the DNA breaks associated 
with immunoglobulin gene remodeling mechanisms 
involved  in  the  production  of  high-affinity  antibodies 
of different isotypes [114]. Moreover, BCL6 function 
appeared to be relevant on a number of not previously 
considered cellular pathways by modulating signaling 
through Toll-like receptors and Wnt signaling [109,115]. 
Of importance, deregulated BCL6 expression is associated 
with lymphoma genesis, at least in part by allowing the 
occurrence of genetic aberrations in an environment 
unresponsive to DNA damage checkpoints and by 
interfering with the differentiation processes [114].
Although the BCL6 gene is increased in 
preeclamptic  placentas  [27,37],  its  biological  function 
remains to be elucidated. It is tempting to speculate that 
increased BCL6 in preeclampsia may be associated with 
deregulated DNA-damage response, cell cycle arrest, 
cell survival, cell differentiation and immune response 
in trophoblast cells. It is of importance to find out its 
protein levels in different gestational stages, subcellular 
localization, function and its involvement in molecular 
networks, which could provide a better understanding for 
preeclampsia pathogenesis. In particular, it is intriguing to 
explore the DNA-damage response and repair signaling 
in cytotrophoblast in the presence of hypoxia and 
oxidative stress, in context of highly expressed BCL6 in 
preeclamptic placenta.
INHIBIN A (INHA)
Another important gene reported by several 
studies  is  INHA  [27,28,32,36,37,116].  Inhibin A  is  a 
growth and differentiation factor belonging to the TGF-β 
superfamily. It is a dimeric, disulfide-linked glycoprotein 
hormone, consisting of an α-subunit and one of several 
β-subunits, including inhibin A (a-βA) and inhibin B (a-
βB) [117]. Previous studies have reported that inhibin A 
level was significantly elevated in the maternal serum 
of preeclampsia patients [118,119]. It is mainly derived 
from placental trophoblasts during pregnancy [120], as 
maternal concentrations of inhibin A are quickly decreased 
to a low level after the removal of the placenta [121]. It 
has been considered that increasing inhibin A may be 
induced by syncytiotrophoblastic inflammatory cytokines 
or placental oxidative stress in preeclampsia [122]. The 
increase in inhibin A seems more likely to be a placental 
compensation mechanism in preeclampsia to adjust the 
placental function [123].
LEPTIN (LEP)
Finally, the most strikingly gene altered in 
preeclampsia is LEP, which is up-regulated reported by 
multiple  microarray  studies  [27-32,36,37],  supporting 
the previous results [124-126]. In accordance with this 
finding, leptin is increased in circulation of preeclampsia 
patients  [127-129].  It  is  produced  by  adipocytes  both 
in adult and fetus, and is highly expressed in placenta, 
which is not affected by maternal body mass index 
[29]. Functionally, leptin activates its receptor signaling 
pathways in trophoblast cells and exerts an anti-
apoptotic and proliferative effect on human placenta 
[130]. Moreover, leptin stimulates protein synthesis by 
activating the translational machinery [130]. Interestingly, 
it has been recently shown that leptin may promote the 
ability of endothelial progenitor cells to participate in 
vascular remodeling [131]. Thus, increased production Oncotarget 2012; 3: 759-773 768 www.impactjournals.com/oncotarget
of leptin, in combination with human chorionic 
gonadotropin (hCG) and other angiogenic factors secreted 
by the poorly perfused preeclamptic placenta, may be a 
compensatory mechanism against endothelial dysfunction 
observed in preeclampsia. However, a clear picture of 
how an increased leptin is linked to the pathogenesis of 
preeclampsia remains to be elucidated.
On the other hand, leptin is also associated with 
malignancy development, in particular, in breast cancer. 
Interestingly, it is well recognized that obesity is associated 
with increased risk of more aggressive breast cancer as 
well as reduced survival of the cancer patient [132,133]. 
Obesity  is  associated  with  increased  inflammation, 
angiogenesis, and alterations in serum levels of potential 
growth regulators [134,135]. Both the adipocytes as 
well as the non-adipocyte fraction of the adipose tissue 
synthesize and secrete several adipokines including leptin, 
tumour necrosis factor (TNF)-α, interleukin-6 (IL-6) and 
hepatocyte growth factors (HGF), which are also well 
known to be involved in the pathogenesis of preeclampsia. 
Leptin exerts its metabolic effects as well as biological 
activities, such as cell proliferation, apoptosis and survival 
on breast cancer cells [136,137].
SUMMARY
Taken together, the data from these 18 microarray-
based studies display multiple pictures of gene profiles, 
highlighting the heterogeneous pathophysiology of 
preeclampsia. Despite the complex of gene signatures, 
these studies demonstrate that a number of genes 
associated with angiogenesis and immune response 
are differentially expressed in preeclamptic placenta, 
compared to normotensive placenta. Importantly, most 
of  these  identified  genes,  such  as  FLT1,  EBI3,  LEP 
and BCL6, are highly involved in angiogenesis and 
immune modulation in malignant tumor progression. 
Intriguingly, genes involved in apoptosis, proliferation 
and  inflammation  are  less  reported  among  these 
microarray studies, not supportive of the results from 
immunohistochemistry or Western blots. Further studies 
are warranted to corroborate the involvement of specific 
genes  identified  in  these  studies  by  using  more  strict 
design with comparable parameters, like gestational age, 
probe sampling and data analysis strategy. Molecular 
understanding of each interesting gene in signaling 
pathways, such as TGF-β, Wnt, Notch, STAT and VEGF 
related-pathways, may provide novel tools for designing 
new prevention and therapy for preeclampsia. Moreover, 
as illustrated in Fig. 1, many molecular mechanisms in 
trophoblastic cells, linked to migration and invasion, 
angiogenesis, immune tolerance, proliferation and 
differentiation, apoptosis and survival, are also exploited 
by malignant cells to set up supportive environment, 
to evade apoptosis and to escape the host immune 
response [4]. The molecular mechanisms which surrender 
trophoblasts immobile and trigger baneful immune 
response in preeclamptic placenta will shed new light on 
cancer research. 
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